GlassScriptPhysician profile
Robert Lee Bloomfield
NPI 1962496810
$2,015.38
in general payments reported to CMS, 2019-2025
25 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $89.08 · 2021: $441 · 2022: $382 · 2023: $279 · 2024: $59.63 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $315.47 | 2019-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $289.05 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $256.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.36 | 2019-2023 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $164.59 | 2022-2025 | Keveyis |
| Kowa Pharmaceuticals America, INC. | $125.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.12 | 2022-2023 | |
| Pfizer INC. | $69.53 | 2022-2025 | |
| Janssen Biotech, INC. | $67.00 | 2021 | |
| Amarin Pharma, INC. | $51.53 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.57 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $42.99 | 2022-2023 | Verquvo |
| Strongbridge US INC. | $35.11 | 2019-2020 | |
| Corcept Therapeutics | $33.50 | 2025 | Korlym |
| Mylan Specialty L.P. | $27.83 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $25.05 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $24.94 | 2025 | |
| Paratek Pharmaceuticals, INC. | $18.45 | 2023 | Nuzyra |
| Glaxosmithkline, LLC. | $16.13 | 2024 | Arexvy, Trelegy Ellipta |
| Scpharmaceuticals INC. | $14.77 | 2025 | |
| Medicure Pharma INC. | $13.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.47 | 2021 | |
| Linus Health, INC. | $12.79 | 2023 | |
| Astellas Pharma US INC | $11.67 | 2021 | |
| Zyla Life Sciences, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bloomfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.